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require additional dual antiplatelet therapy with aspirin and clopidogrel. Such triple therapy confers an elevated bleeding
risk, and its optimal duration is not known.
OBJECTIVES The goal of this study was to evaluate whether shortening the duration of clopidogrel therapy from
6 months to 6 weeks after DES implantation was associated with a superior net clinical outcome in patients receiving
concomitant aspirin and OAC.
METHODS In this randomized, open-label trial, we enrolled patients receiving OAC who underwent DES implantation at
3 European centers between September 2008 and December 2013. A total of 614 patients receiving concomitant aspirin
and OAC were randomized to either 6-week clopidogrel therapy (n ¼ 307) or 6-month clopidogrel therapy (n ¼ 307). The
primary endpoint was a composite of death, myocardial infarction (MI), deﬁnite stent thrombosis, stroke, or Thrombolysis
In Myocardial Infarction (TIMI) major bleeding at 9 months.
RESULTS The primary endpoint occurred in 30 patients (9.8%) in the 6-week group compared with 27 patients (8.8%)
in the 6-month group (hazard ratio [HR]: 1.14; 95% CI: 0.68 to 1.91; p ¼ 0.63). There were no signiﬁcant differences
for the secondary combined ischemic endpoint of cardiac death, MI, deﬁnite stent thrombosis, and ischemic stroke
(12 [4.0%] vs. 13 [4.3%]; HR: 0.93; 95% CI: 0.43 to 2.05; p ¼ 0.87) or the secondary bleeding endpoint of TIMI major
bleeding (16 [5.3%] vs. 12 [4.0%]; HR: 1.35; 95% CI: 0.64 to 2.84; p ¼ 0.44).
CONCLUSIONS Six weeks of triple therapy was not superior to 6 months with respect to net clinical outcomes. These
results suggest that physicians should weigh the trade-off between ischemic and bleeding risk when choosing the shorter
or longer duration of triple therapy. (Triple Therapy in Patients on Oral Anticoagulation After Drug Eluting Stent
Implantation [ISAR-TRIPLE]; NCT00776633) (J Am Coll Cardiol 2015;65:1619–29) © 2015 by the American College
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1620P atients undergoing percutaneous cor-onary intervention (PCI) require dualantiplatelet therapy (DAPT) consist-
ing of aspirin and a thienopyridine, a
regimen proven superior to oral anticoagula-
tion (OAC) for the prevention of subsequent
stent thrombosis (1,2). However, randomized
trials have shown that DAPT is inferior to
OAC for reducing the risk of thromboembolic
events in patients with atrial ﬁbrillation
(3) or with mechanical heart valves (4).
Accordingly, it is recommended that patients
receiving OAC and undergoing PCI receive
triple therapy, typically consisting of aspirin,
clopidogrel, and an oral anticoagulant (5,6).SEE PAGE 1630The optimal duration of triple therapy after PCI
remains to be deﬁned, and 2 factors need consider-
ation. First, the risk of stent thrombosis (ST) is high-
est in the early phase after PCI and declines over time
(7). Secondly, the risk of bleeding with triple therapy
increases with duration of therapy (8,9) and intensity
of OAC (10). Current guidelines for patients on OAC
undergoing PCI were drafted mainly on the basis of
observational data and state that a minimum of 4
weeks of triple therapy after bare-metal stent (BMS)
implantation and 1 to 12 months of therapy after drug-
eluting stent (DES) implantation should be consid-
ered (5,6,11,12). On the basis of data from 1 random-
ized trial (13), dual therapy of an OAC and clopidogrel
may be considered as an alternative to initial triple
therapy in selected patients (6,11). The duration of
therapy after DES implantation is a matter of partic-
ular importance because patients are sometimes de-
nied this highly effective treatment due to a
perceived need for extended-duration triple therapy.
The objective of the ISAR-TRIPLE (Intracoronary
Stenting and Antithrombotic Regimen–Testing of a
6-Week Versus a 6-Month Clopidogrel Treatment
Regimen in Patients With Concomitant Aspirin and
Oral Anticoagulant Therapy Following Drug-Eluting; and research grants from Roche Diagnostics. Dr. Byrne has rec
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received November 19, 2014; revised manuscript received FebruStenting) trial was to assess whether a 6-week clopi-
dogrel treatment after DES implantation was associ-
ated with a superior net clinical outcome compared
with a 6-month clopidogrel treatment in patients
receiving concomitant aspirin and OAC.
METHODS
STUDY DESIGN AND PATIENTS. In this randomized,
open-label trial, we enrolled patients at 2 centers
in Germany (Deutsches Herzzentrum and Klinikum
rechts der Isar, both in Munich) and at 1 center in
Denmark (Aarhus University Hospital in Aarhus) be-
tween September 2008 and December 2013. Eligible
patients must have been receiving OAC for at least
12months and receiving aDES for stable anginaor acute
coronary syndrome. Major exclusion criteria were age
#18 years, previous ST, DES implantation in the left
main stem, active bleeding or bleeding diathesis, or a
history of intracranial bleeding. The design and ratio-
nale of the ISAR-TRIPLE trial, including the full list of
exclusion criteria, was reported previously (14).
The study was conducted in accordance with the
provisions of the Declaration of Helsinki and the
International Conference on Harmonisation Good
Clinical Practice guidelines. The institutional ethics
committee responsible for the participating centers
approved the trial protocol. All patients provided
written informed consent.
RANDOMIZATION. Randomization to a 6-week versus
6-month duration of clopidogrel therapy after DES
implantation was performed with a treatment allo-
cation of 1:1 by means of sealed opaque envelopes
containing a computer-generated sequence (ISARe-
search Centre, Munich) for the German patients and
by a computer-generated web-based system (Aarhus
University Hospital, Aarhus) for the Danish patients.
Patients were considered enrolled in the study and
eligible for the ﬁnal intention-to-treat analysis at
the time of randomization.
TREATMENT. Coronary angiography was performed
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1621recommendation was provided in the protocol re-
garding the vascular access site. Patients received a
loading dose of clopidogrel 300 to 600 mg before PCI.
Peri-interventional therapy with heparin or bivalir-
udin was at the discretion of the treating physician,
and glycoprotein IIb/IIIa inhibitor use was discour-
aged. Aspirin-naive patients received 500 mg of
intravenous aspirin. Because the study was un-
blinded, commercially available drugs were given
according to the protocol. During the study, patients
received clopidogrel 75 mg daily for 6 weeks or
6 months; aspirin 75 to 200 mg once daily, according
to local standards; and a vitamin K antagonist with
either phenprocoumon or warfarin. OAC therapy was
prescribed with the lowest recommended target in-
ternational normalized ratio (INR) during the dura-
tion of triple therapy.
ASSESSMENTS AND FOLLOW-UP. Patients were evalu-
ated by telephone call or at physician ofﬁce visits
after 6 weeks, 6 months, and 9 months to obtain
detailed information regarding the occurrence of
endpoints, adverse events, and patient compliance
with the study medication.
The primary endpoint of the study was a composite
of death, myocardial infarction (MI), deﬁnite ST (15),
stroke, or Thrombolysis In Myocardial Infarction
(TIMI) major bleeding (16) at 9 months after ran-
domization. Secondary endpoints were the incidence
of ischemic complications (cumulative incidence
of cardiac death, MI, deﬁnite ST, or ischemic stroke)
or bleeding complications (TIMI major bleeding), and
each individual component of the primary and sec-
ondary endpoint was assessed separately. Bleeding
events were also classiﬁed according to the Bleeding
Academic Research Consortium (BARC) criteria (16).
A detailed description of the endpoint deﬁnitions
was recently published (14). Events were adjudi-
cated and classiﬁed by an event adjudication com-
mittee whose members were unaware of the assigned
treatment.
STATISTICAL ANALYSIS. The study was designed to
assess whether a 6-week clopidogrel treatment
after DES in patients receiving aspirin and OAC was
associated with a net clinical outcome (composite
of death, MI, deﬁnite ST, stroke, or TIMI major
bleeding) superior to that of a 6-month clopidogrel
treatment in patients receiving aspirin and OAC. The
incidence of the primary endpoint was assumed to be
10% with a 6-month clopidogrel therapy and a risk
reduction of 60% with a 6-week clopidogrel therapy;
a power of 80% and an alpha level of 0.05 were
applied. Accordingly, 283 patients were needed in
each group.Categorical variables, such as demographics and
medical history data, were summarized using fre-
quencies and proportions and were compared using
the chi-square test or Fisher exact test, as appro-
priate. Continuous data were summarized using
mean  SD or median (25th, 75th percentiles) and
compared using the Student t test or nonparametric
Wilcoxon rank-sum test. All tests were 2 sided, and an
alpha level of 0.05 was considered statistically sig-
niﬁcant. No adjustments were made for the primary
and secondary endpoint comparisons. Risk estimates
were calculated by Cox analysis. The Kaplan-Meier
method was used for building event curves. For
assessment of events occurring after 6 weeks, a post-
hoc landmark analysis was performed. Analysis of the
primary endpoint was performed in pre-speciﬁed
subgroups deﬁned by age, sex, diabetes, history of
stroke, history of bleeding, hypertension, clinical
presentation, indication for OAC, ejection fraction,
and renal function. The interaction between the
assigned treatment and baseline variable with respect
to the primary endpoint was assessed by the inter-
action term being entered into the respective Cox
proportional model to check the heterogeneity of
treatment differences across the levels of a baseline
variable. We did sample size calculation with nQuery
Advisor (version 7.0, Statistical Solutions, Cork,
Ireland). All statistical analyses were performed with
the software R (version 2.15.0).
RESULTS
PATIENTS. A total of 614 patients were enrolled, of
whom 307 were randomly assigned to the 6-week
group and 307 to the 6-month group (Online
Figure 1). Table 1 shows baseline clinical and de-
mographic characteristics of the patients. Atrial
ﬁbrillation or ﬂutter was the indication for OAC in 254
patients (82.7%) in the 6-week group and 261 patients
(85.0%) in the 6-month group. Approximately two-
thirds of all patients presented with stable angina.
Ninety-eight percent of patients underwent cathe-
terization using femoral access. The majority of
patients received new-generation DES (Table 2). All
but 1 patient received unfractionated heparin during
the procedure, and no patient received glycoprotein
IIb/IIIa inhibitors.
Aspirin therapy was used in 96.7%, 95.0%, and
96.0% of patients at the 6-week, 6-month, and
9-month follow-up time points, respectively, with
no difference between the 2 groups. OAC therapy
was used in 93.7%, 90.6%, and 88.5% of patients at
6 weeks, 6 months, and 9 months, respectively, with
no difference between the 2 groups. Median INR
TABLE 1 Clinical Characteristics and Treatment
6-Week Group
(n ¼ 307)
6-Month Group
(n ¼ 307)
Clinical baseline characteristics
Age, yrs 73.9  7.7 73.3  8.7
Female 78 (25.4) 65 (21.2)
Body mass index, kg/m2 27.5  4.2 27.9  4.6
Diabetes 85 (27.7) 72 (23.5)
Insulin dependent 24 (7.8) 23 (7.5)
Arterial hypertension 236 (76.9) 232 (75.6)
Hypercholesterolemia 227 (73.9) 230 (74.9)
Current smoker 28 (9.1) 32 (10.4)
History of myocardial infarction 90 (29.3) 76 (24.8)
History of CABG* 73 (23.8) 51 (16.6)
Multivessel disease 221 (72.0) 216 (70.3)
Clinical presentation on admission
STEMI 3 (1.0) 2 (0.7)
NSTEMI 50 (16.3) 41 (13.4)
Unstable angina pectoris 49 (16.0) 52 (16.9)
Stable angina pectoris 205 (66.8) 212 (69.1)
Medication at discharge
Aspirin 307 (100) 307 (100)
Clopidogrel 307 (100) 307 (100)
Beta-blocker 265 (86.3) 269 (87.6)
ACE inhibitor 197 (64.2) 198 (64.5)
ARB 71 (23.1) 72 (23.4)
Calcium-channel blocker 70 (22.8) 79 (25.7)
Diuretic 210 (68.4) 202 (65.8)
Statin 262 (85.3) 260 (84.7)
Indication for oral anticoagulation†
Atrial ﬁbrillation or ﬂutter 254 (82.7) 261 (85.0)
Mechanical valve 17 (5.5) 28 (9.1)
Venous thromboembolism 23 (7.5) 11 (3.6)
Other 13 (4.2) 7 (2.3)
Stroke risk for patients with AF‡
CHADS2 score
0 5 (2.0) 5 (1.9)
1 37 (14.6) 50 (19.2)
2 79 (31.1) 90 (34.5)
3 76 (29.9) 78 (29.9)
4 36 (14.2) 28 (10.7)
5 15 (5.9) 7 (2.7)
>5 6 (2.3) 3 (1.1)
CHA2DS2-VASc Score
1 0 1 (0.4)
2 12 (4.7) 18 (6.9)
3 27 (10.6) 42 (16.1)
4 69 (27.2) 70 (26.8)
5 70 (27.6) 74 (28.4)
6 50 (19.7) 38 (14.6)
7 16 (6.3) 14 (5.4)
8 8 (3.1) 2 (0.8)
9 2 (0.8) 2 (0.8)
Values are mean  SD or n (%). *p ¼ 0.03. †p ¼ 0.03. ‡n ¼ 254 in the 6-week group and n ¼ 261
in the 6-month group.
ACE ¼ angiotensin-converting enzyme; AF ¼ atrial ﬁbrillation; ARB ¼ angiotensin II receptor
blocker; CABG ¼ coronary artery bypass graft; CHADS2 ¼ congestive heart failure, hypertension,
age $75 years, diabetes mellitus, stroke/transient ischemic attack; CHA2DS2-VASc ¼ congestive
heart failure, hypertension, age $75 years, diabetes mellitus, stroke/transient ischemic attack,
vascular disease, age 65 to 74 years, sex category; NSTEMI ¼ non–ST-segment elevation
myocardial infarction; STEMI ¼ ST-segment elevation myocardial infarction.
TABLE 2 Angiographic Characteristics According to
Treated Lesions
6-Week Group
(n ¼ 417)
6-Month Group
(n ¼ 409)
Stent type
EES 158 (37.9) 160 (39.1)
Biodegradable polymer BES 69 (16.5) 64 (15.7)
Biodegradable polymer SES 62 (14.9) 70 (17.1)
ZES 45 (10.8) 46 (11.2)
Probucol SES 45 (10.8) 46 (11.2)
PES 20 (4.8) 12 (2.9)
SES 9 (2.1) 4 (1.0)
Bioresorbable EES 4 (1.0) 3 (0.7)
BMS* 2 (0.5) 0
DEB/PTCA† 3 (0.7) 4 (1.0)
PCI vessel
LAD 177 (42.4) 173 (42.3)
LCX 102 (24.5) 73 (17.8)
RCA 110 (26.4) 143 (35.0)
Left main stem‡ 7 (1.7) 5 (1.2)
Bypass graft 21 (5.0) 15 (3.7)
Stented length, mm 25.3  13.3 25.6  13.3
Stents per lesion 1.3  0.5 1.3  0.5
Values are n (%) or mean  SD. *One patient had 1 EES and 1 BMS, and 1 patient
had 1 BMS only. †These patients were treated with drug-eluting balloons (DEB),
except for 1 patient in the 6-week group and 1 patient in the 6-month group. ‡Four
of the 7 left main stem lesions in the 6-week group and 4 of the 5 main stem
lesions in the 6-month group had a previous bypass graft.
BES ¼ biolimus-eluting stent; BMS ¼ bare-metal stent(s); EES ¼ everolimus-
eluting stent(s); LAD ¼ left anterior descending; LCX ¼ left circumﬂex; PCI ¼
percutaneous coronary intervention; PES¼ paclitaxel-eluting stent(s); PTCA/DEB¼
percutaneous transluminal coronary angioplasty/drug-eluting balloon; RCA¼ right
coronaryartery;SES¼sirolimus-elutingstent(s);ZES¼zotarolimus-elutingstent(s).
Fiedler et al. J A C C V O L . 6 5 , N O . 1 6 , 2 0 1 5
Duration of Triple Therapy A P R I L 2 8 , 2 0 1 5 : 1 6 1 9 – 2 9
1622values (interquartile range) were 2.2 (1.9 to 2.7), 2.3
(2.0 to 2.6), and 2.3 (2.0 to 2.6) at 6 weeks, 6 months,
and 9 months, respectively, with no difference
between the 2 groups. At 6 weeks, 6 months, and
9 months, INR values were within the therapeutic
range (2.0 to 3.0) in 63.7%, 68.9%, and 66.1% of pa-
tients, respectively, with no difference between the
2 groups.
At discharge, 37.3% of patients were treated with
proton pump inhibitors, with no difference between
groups.
OUTCOMES. Follow-up at 9 months was completed
for 302 patients (98.4%) assigned to 6-week therapy
and 304 patients (99.0%) assigned to 6-month ther-
apy. The primary endpoint of death, MI, deﬁnite ST,
stroke, or TIMI major bleeding occurred in 30 patients
(9.8%) in the 6-week group compared with 27 patients
(8.8%) in the 6-month group (hazard ratio [HR]: 1.14;
95% CI: 0.68 to 1.91; p ¼ 0.63) at 9 months (Figure 1A,
Table 3). The lack of treatment effect was consistent
across all pre-speciﬁed subgroups deﬁned by age,
sex, diabetes, history of stroke, history of bleeding,
J A C C V O L . 6 5 , N O . 1 6 , 2 0 1 5 Fiedler et al.
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1623hypertension, clinical presentation, indication for
OAC, ejection fraction, and renal function (Online
Figure 2).
Regarding secondary endpoints, the combined
ischemic endpoint of cardiac death, MI, deﬁnite ST, or
ischemic stroke was reported in 12 patients (4.0%)
in the 6-week group and 13 patients (4.3%) in the
6-month group (HR: 0.93; 95% CI: 0.43 to 2.05;
p ¼ 0.87) (Figure 1B). There were 6 cases (2.0%) of
MI in the 6-week group, compared with none in the
6-month group (p ¼ 0.03). Three MIs were peri-
procedural, occurring within 24 h of PCI; 1 patient
had deﬁnite ST on the day of PCI; 1 patient had deﬁ-
nite ST on day 17 while receiving triple therapy; andFIGURE 1 Cumulative Incidence of the Primary, Secondary Ischemic,
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Kaplan-Meier analysis of the (A) primary endpoint (cumulative incidence
Infarction [TIMI] major bleeding), (B) secondary ischemic endpoint (card
bleeding endpoint (TIMI major bleeding) at 9 months. HR ¼ hazard rati1 MI occurred on day 212 while the patient was
receiving OAC and aspirin.
A potential rebound phenomenon was the reason
for moving the endpoints from 6 to 9 months.
Without this 3-month extension, a possible rebound
phenomenon would have disadvantaged only the 6-
week group. However, Figure 1B shows no excess
ischemic events in either group in the 3 months
following the discontinuation of study treatment.
There was no difference in TIMI major bleeding
between the 2 groups (16 [5.3%] vs. 12 [4.0%]; HR:
1.35; 95% CI: 0.64 to 2.84; p ¼ 0.44) (Figure 1C). Any
BARC bleeding occurred in 114 patients (37.6%) in
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o.
TABLE 3 Results for Primary and Secondary Endpoints at 9 Months and in Landmark Analysis From 6 Weeks to 9 Months
Outcome at 9 Months Landmark Analysis 6 Weeks to 9 Months
6-Week Group
(n ¼ 307)
6-Month Group
(n ¼ 307)
Hazard Ratio
(95% CI)
p
Value
6-Week
Group
6-Month
Group
Hazard Ratio
(95% CI)
p
Value
Primary endpoint
Death, MI, stent thrombosis,
stroke or major bleeding
30 (9.8) 27 (8.8) 1.14 (0.68–1.91) 0.63 13 (4.6) 19 (6.4) 0.70 (0.35–1.42) 0.32
Secondary endpoints
Cardiac death, myocardial infarction
stent thrombosis or ischemic stroke
12 (4.0) 13 (4.3) 0.93 (0.43–2.05) 0.87 4 (1.4) 10 (3.4) 0.40 (0.13–1.24) 0.13
TIMI major bleeding 16 (5.3) 12 (4.0) 1.35 (0.64–2.84) 0.44 7 (2.4) 7 (2.4) 1.01 (0.35–2.88) 0.99
Death 12 (4.0) 16 (5.2) 0.75 (0.35–1.59) 0.45 8 (2.7) 12 (4.0) 0.66 (0.27–1.63) 0.37
Cardiac death 5 (1.7) 9 (3.0) 0.56 (0.19–1.66) 0.29 3 (1.0) 8 (2.7) 0.37 (0.10–1.34) 0.15
MI 6 (2.0) 0 — 0.03 1 (0.03) 0 — >0.99
Periprocedural MI 3 (1.0) 0 — 0.25 — — — —
Deﬁnite stent thrombosis 2 (0.7) 0 — 0.50 0 0 — —
Stroke 4 (1.3) 6 (2.0) 0.67 (0.19–2.35) 0.53 2 (0.7) 2 (0.7) 0.99 (0.14–7.05) 0.99
Ischemic stroke 3 (1.0) 4 (1.3) 0.75 (0.17–3.34) 0.71 1 (0.03) 2 (0.7) 0.5 (0.05–5.24) 0.57
TIMI major and minor bleeding 35 (11.5) 30 (9.9) 1.18 (0.73–1.93) 0.49 14 (5.0) 15 (5.2) 0.95 (0.46–1.97) 0.90
TIMI major bleeding 16 (5.3) 12 (4.0) 1.35 (0.64–2.84) 0.44 7 (2.4) 7 (2.4) 1.01 (0.35–2.88) 0.99
TIMI minor bleeding 19 (6.3) 18 (5.9) 1.06 (0.56–2.03) 0.85 7 (2.4) 8 (2.8) 0.88 (0.32–2.44) 0.81
Any BARC bleeding 114 (37.6) 122 (40.2) 0.94 (0.73–1.21) 0.63 48 (20.5) 70 (27.9) 0.68 (0.47–0.98) 0.04
BARC 1 58 (19.4) 57 (19.1) 1.03 (0.72–1.49) 0.87 28 (10.6) 37 (13.4) 0.76 (0.47–1.25) 0.29
BARC 2 22 (7.3) 33 (10.9) 0.66 (0.38–1.13) 0.13 7 (2.5) 17 (6.0) 0.40 (0.17–0.97) 0.04
BARC 3a 14 (4.6) 17 (5.6) 0.83 (0.41–1.68) 0.60 4 (1.4) 8 (2.8) 0.50 (0.15–1.63) 0.26
BARC 3b 17 (5.6) 13 (4.3) 1.32 (0.64–2.72) 0.45 7 (2.4) 8 (2.7) 0.89 (0.32–2.44) 0.81
BARC 3c 0 0 — — 0 0 — —
BARC 4 0 0 — — 0 0 — —
BARC 5a 0 1 (0.03) — >0.99 0 0 — —
BARC 5b 3 (1.0) 1 (0.03) 3.00 (0.34–25.8) 0.34 2 (0.7) 0 — 0.50
BARC bleeding $ 2 56 (18.4) 65 (21.3) 0.86 (0.60–1.23) 0.41 20 (7.6) 33 (12.2) 0.60 (0.34–1.04) 0.07
Values are n (Kaplan Meier Estimates), unless otherwise noted.
BARC ¼ Bleeding Academic Research Consortium criteria; MI ¼ myocardial infarction; TIMI ¼ Thrombolysis In Myocardial Infarction criteria.
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16246-month group (HR: 0.94; 95% CI: 0.73 to 1.21;
p ¼ 0.63) (Figure 2A). Intracranial bleeding frequency
was low (Online Table 1). More than one-half of all
bleedings were localized in the nose or skin, followed
by gastrointestinal and access site bleeds.
Compliance with assigned clopidogrel therapy at
6 weeks was 97.7% in the 6-week group and 98.4%
in the 6-month group (p ¼ 0.56), 73.6% and 86.6% (p <
0.001) at 6 months, and 76.6% and 64.5% (p< 0.001) at
9 months (Online Figure 1). Of patients who were
nonadherent to clopidogrel therapy at 6 months, the
primary endpoint occurred in 13 of 81 (16.0%) in the
6-week group and 3 of 41 (7.7%) in the 6-month group.
The secondary ischemic endpoint occurred in 6 pa-
tients (7.4%) in the 6-week group and none in the
6-month group. The secondary TIMI major bleeding
endpoint occurred in 5 patients (6.3%) in the 6-week
group and 2 patients (4.9%) in the 6-month group.
LANDMARK ANALYSES. By protocol, both groups
were treated with the same triple therapy regimenfor the ﬁrst 6 weeks. Thereafter, 1 group received
aspirin and OAC only, whereas the other group
continued the triple therapy regimen until 6 months.
To compare outcomes attributed to the period when
treatment between the groups separated, we per-
formed a post-hoc landmark analysis from 6 weeks
to 9 months, which revealed no signiﬁcant differ-
ences regarding the primary or secondary endpoints
(Table 3). There were signiﬁcantly fewer bleeding
events according to any BARC bleeding (48 [20.5%]
vs. 70 [27.9%]; HR: 0.68; 95% CI: 0.47 to 0.98;
p ¼ 0.04) in landmark analysis of the 6-week group
(Figure 2B, Table 3) and fewer bleeding events ac-
cording to the cumulative incidence of BARC type
2 or higher bleeding in landmark analysis of the
6-week group (Central Illustration).
We also performed a landmark analysis for the time
period when recommendations for treatment were
truly different. In the landmark analysis from 6 weeks
to 6 months, there were no signiﬁcant differences
regarding the primary or secondary endpoints. This
FIGURE 2 Cumulative Incidence of BARC Types 1 to 5 Bleeding at 9 Months and in Landmark Analysis
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1625analysis revealed an even more pronounced reduc-
tion in bleeding complications in the 6-week group
according to any BARC bleeding, BARC type 2
bleeding, and the cumulative incidence of BARC
type 2 or higher bleeding (Online Table 2).
DISCUSSION
In this randomized trial of patients with an indication
for OAC undergoing DES implantation, we compared
regimens of 6 weeks and 6 months of clopidogrel
therapy in the setting of concomitant aspirin and
OAC therapy. The main ﬁndings are as follows:
1) 6 weeks compared with 6 months of triple therapy
was not superior with regard to net clinical outcomes
and 2) neither the composite of ischemic complica-
tions nor major bleedings was statistically signiﬁ-
cantly different between the treatment groups.
Balancing ischemic and bleeding risk is of the
utmost importance in patients treated with clopi-
dogrel, especially in those receiving triple therapy.
Premature discontinuation of antiplatelet therapy
might increase the risk of ST (7), whereas prolonged
therapy has been associated with more bleeding
events (8). Current recommendations for duration
of triple therapy in patients on OAC undergoing cor-
onary stent implantation differ between European
and North American consensus statements (5,6).
Whereas European authorities recommend triple
therapy durations after DES implantation of 1 to6 months, North American experts mostly recom-
mend a 12-month course (5,17). This discordance is
not surprising because the current evidence for DAPT
duration in patients on OAC is lacking. DAPT is
generally recommended for at least 4 weeks for BMS
and 6 months for DES. In the current trial, 6 weeks
of DAPT was chosen to provide patients receiving
DES with a DAPT duration close to that required in
patients receiving BMS, under the assumption that
further protection from ST might also be offered by
the presence of OAC. Additionally, the optimal dura-
tion of clopidogrel therapy after DES implantation in
patients not receiving OAC has shown no uniform
results (18,19). Indeed, there is recent evidence to
support the use of shorter durations of DAPT in
selected patients receiving newer-generation DES
not concomitantly treated with OAC (20–23).
The ISAR-TRIPLE trial is the ﬁrst trial evaluating
the optimal duration of clopidogrel therapy in pa-
tients treated with DES who have an indication for
OAC. The principal ﬁnding was that the primary
endpoint—a composite of death, MI, ST, stroke, or
TIMI major bleeding, also referred to as net clinical
outcome—was not superior after a 6-week compared
with 6-month duration of triple therapy. Because
both ischemic and bleeding events impact mortality
after PCI (24,25), net clinical outcome was chosen as
the primary endpoint to reﬂect the aggregate effect
on patient outcomes. This is in keeping with prior
studies of antithrombotic and antiplatelet therapy
CENTRAL ILLUSTRATION Duration of Triple Therapy: Cumulative Incidence of BARC Type $2 Bleeding
Before and After 6 Weeks
Fiedler, K.A. et al. J Am Coll Cardiol. 2015; 65(16):1619–29.
Kaplan-Meier analysis of Bleeding Academic Research Consortium (BARC) type $2 bleeding before and after 6 weeks (6w). HR ¼ hazard ratio.
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1626in PCI (26). The power in our study was calculated
on the basis of our expectation of a considerable
decrease in the number of bleeding complications.
Although it might be argued that the magnitude of
the assumed reduction was high, the difference in
the duration of exposure to triple therapy in both
groups was large. Moreover, previous trials also
assumed—and were able to demonstrate—a reduction
in the number of bleeding complications on the order
of 60% (13), and observational data have shown that
the frequency of bleeding events may be reduced
by 40% with dual compared with triple therapy (27).
Notwithstanding these concerns, the present trial
is the largest randomized trial to date investigating
triple therapy after stent implantation.
There was no difference in major bleeding events
between patients treated with a 6-week or 6-month
duration of clopidogrel therapy. This may at ﬁrst
seem surprising. Indeed, major bleeding (5.3% vs.4.0%, respectively) deﬁned according to TIMI criteria
as well as BARC types 2 to 5 bleeding was similar in
both groups. However, the rates of TIMI major
bleeding were comparable to those in the earlier
WOEST (What Is the Optimal Antiplatelet & Antico-
agulant Therapy in Patients With Oral Anti-
coagulation and Coronary Stenting) randomized trial,
and, in that trial, omitting aspirin also failed to
signiﬁcantly reduce the number of major hemorrhagic
complications (13). This underlines the challenge of
reducing the risk of major bleeding events in this
patient population. The frequency of any bleeding
event in this trial was high—approximately 40% of
patients suffered from any bleeding according to
BARC during the 9-month study period, with no sig-
niﬁcant difference between the treatment groups.
These ﬁndings are numerically similar to the results
of the WOEST trial, in which the number of any
bleeding episodes at 12 months was 44% in patients
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1627receiving triple therapy. Other studies evaluating
safety and efﬁcacy of triple therapy have found lower
rates of any bleeding events—on the order of 15% to
20% (8,9,28,29); however, populations, bleeding
deﬁnitions, and study designs differed substantially.
There was also no extra risk of the composite
ischemic endpoint with shorter duration therapy
observed in the present study. The absence of dif-
ferences in relation to the composite ischemic end-
point may be important but requires qualiﬁcation
by examination of the individual components of
this endpoint. First, the rate of cardiac death was
low and comparable in both groups. The overall rate
of ST was low in both groups (0.7% vs. 0.0%). This
lends some support to the strategy of DAPT for the
initial weeks after PCI. The rate of MI was higher in
the 6-week group (2.0% vs. 0.0%). This might theo-
retically represent a signal of reduced efﬁcacy;
however, examination of their temporal distribution
showed that all of the events occurred at a time
point when treatment between groups did not differ
(i.e., before 6 weeks or after 6 months). Therefore,
this ﬁnding cannot be attributed to the shorter
duration of clopidogrel therapy and, in our opinion,
likely was due to chance. Finally, the rate of stroke
was comparable in both groups and was in line with
expected risks.
To further evaluate the impact of triple therapy
versus the combination of aspirin and OAC alone, we
performed a post-hoc landmark analysis for the
period after 6 weeks, when treatment regimens be-
tween groups differed. No differences were observed
for major bleeding events at landmark analysis.
However, the 6-month group experienced signiﬁ-
cantly more bleeding events according to any BARC
and BARC types 2 to 5 bleeding. This is of interest
because not only major bleeding events, but also
BARC types 2 to 5 bleeding, are known to have an
impact on patient 1-year survival rates (25). Never-
theless, it must be acknowledged that overall the
ISAR-TRIPLE trial failed to show that a shorter dura-
tion of clopidogrel, from 6 months to 6 weeks, was
associated with lower bleeding rates. An explanation
for this ﬁnding may be that approximately one-half
of all bleeding events occurred in the ﬁrst 6 weeks
after PCI, when both groups received the same ther-
apy consisting of aspirin, clopidogrel, and OAC.
Finally, although our trial was not designed to
show noninferiority with 6-week therapy, compared
with 6-month therapy, comparable results were
seen in both treatment groups. Although these ob-
servations require conﬁrmation in future trials, this
provides some evidence that DES implantation in
these patients may be undertaken without requiringan extended duration of triple therapy. Neverthe-
less, this issue is clinically important because it
suggests that patients receiving OAC—who are typi-
cally older and have more complex coronary artery
disease—could be offered standard of care stent
implantation with DES and a duration of DAPT
comparable to that administered following treat-
ment with BMS.
STUDY LIMITATIONS. First, the ISAR-TRIPLE trial
shares the limitation common to all randomized trials
with an open-label design. Although we tried to
minimize this bias by endpoint analysis according
to the intention-to-treat principle, the use of precise
criteria for endpoint assessment, and the use of
blinded adjudication of events on the basis of original
source data, we cannot fully exclude bias. The trial
was not speciﬁcally powered to detect differences in
the individual components of the primary endpoint,
and any comparisons should be interpreted with
caution. We also acknowledge that the study was only
powered to a fairly large reduction (60%) in events,
and the interaction tests in the subgroup analyses
were also underpowered.
The results of the post-hoc landmark analysis at
6 weeks should be interpreted with caution. More-
over, randomization after 6 weeks might have been
more suitable. However, for pragmatic reasons re-
lated to feasibility of patient enrollment, a number of
recent studies evaluating optimal duration of DAPT
after DES implantation have also randomized patients
at the time of the index procedure (30,31). We did
not investigate the role of new oral anticoagulants or
newer, more potent antiplatelet agents because they
were not approved at the time the study was
designed. Limited data suggest that in the setting of
triple therapy, dabigatran, compared with warfarin,
may reduce (32) and prasugrel, compared with clopi-
dogrel, may increase (33) bleeding rates. However,
the results of this trial will be useful in guiding the
duration of therapy in future trials with novel OACs
and/or ADP receptor antagonists. Noncompliance
with the prescribed clopidogrel regimen was
approximately 25% at the 6-month follow-up time
point. Patients who experience ischemic events may
require prolonged clopidogrel therapy, as with our
patients who were not compliant, which perhaps
inﬂuenced our trial’s negative outcome. However,
these rates were comparable to those in other trials
with antithrombotic therapy (e.g., aspirin noncom-
pliance in the WOEST trial: 33.5% [13], ADP receptor
antagonist noncompliance in the PLATO [Platelet
Inhibition and Patient Outcomes] trial: 22% [34],
and clopidogrel nonadherence in the SECURITY
PERSPECTIVES
COMPETENCY IN MEDICAL KNOWLEDGE:
Antithrombotic therapy in patients with indications
for oral anticoagulation undergoing implantation of
drug-eluting stents is problematic. The optimum
duration of triple therapy with 2 antiplatelet drugs
plus an anticoagulant has not been established and
may differ on the basis of individual patient, stent,
and drug characteristics. A shorter (6-week) course of
triple therapy was not superior to a longer (6-month)
course when both major bleeding and ischemic events
were considered.
TRANSLATIONAL OUTLOOK: Future studies
should delineate the duration of therapy as a function
of patient characteristics; number, location, and
types of stents; and distinguishing features of platelet
inhibitor and anticoagulant drug combinations used.
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1628[Second Generation Drug-Eluting Stent Implantation
Followed by 6- Versus 12-Month Dual Antiplatelet
Therapy] trial: 34% [35]). Finally, duration of ther-
apy may vary according to DES type; however, the
study lacked the power to address speciﬁc treat-
ment needs for different types of DES.
CONCLUSIONS
The ISAR-TRIPLE trial did not show that 6 weeks of
triple therapy was superior to 6 months with regard
to the net clinical outcome. These results suggest
that physicians should weigh the trade-off between
ischemic and bleeding risk when choosing the shorter
or longer duration of triple therapy.
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